China-based late-stage biopharmaceutical company Minghui Pharmaceutical announced on Friday positive topline results from its phase III trial of MH004 (tofacitinib etocomil) ointment 1.0%, a pan-Jak inhibitor, for mild to moderate atopic dermatitis (AD) in adolescents and adults.
The randomized, vehicle-controlled study included 377 participants treated over eight weeks, followed by a 44-week open-label safety extension.
Primary endpoints showed 41.0% of MH004-treated participants achieved Investigator Global Assessment-Targeted Success (IGA-TS) at Week 4, compared to 10.3% with vehicle (P
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001